
Remedy Robotics, a medical technology startup developing AI-powered robotic systems for cardiovascular procedures, has raised $62 million in Series B funding to advance the development and clinical testing of its N1 robotic platform.
The funding round was led by DCVC with participation from new investors UC Investments, Skip Capital and Australian pension fund Hostplus. Existing investors, including Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures, also increased their investments.
According to a press release, the funding was announced by the company on November 16, 2026. The money will be used to finance the necessary clinical trials and regulatory approvals needed for deploying its N1 platform with its clinical partners.
Remedy Robotics was founded by Dr. David Bell and his team. The N1 will use advanced robotics and AI to perform endovascular surgery, thus improving access to treatment for cardiovascular diseases in hospitals without specialized teams.
The N1 platform is designed to perform procedures across three major areas: neurovascular, coronary and peripheral vascular care. Its AI-powered software analyses medical images before procedures, simulates treatment plans and helps doctors align 3D medical images with real-time 2D images during interventions.
The system combines machine-learning software, robotic controls and specialised steerable catheters. It is also being developed to support supervised autonomous procedures and remote operations, allowing specialists to assist patients from different locations.
In October 2025, Remedy Robotics reported completing what it described as the world’s first fully remote neurointerventional procedures. Doctors operated the robotic system from St. Joseph’s Health Centre while patients were located at St. Michael’s Hospital in Toronto, Canada. The procedures were performed robotically without a bedside interventionist.
Remedy Robotics has also established partnerships with more than 100 hospitals worldwide. Its clinical partners include SVIN Mission Thrombectomy, which selected the company as its exclusive robotics partner for N1 testing and development, and the Australian Stroke Alliance, a network representing 40 health organisations.
The company plans to work with the University of California on a pivotal clinical trial. It will also advance regulatory development toward US Food and Drug Administration (FDA) approval for neurovascular interventions.
The investment comes as cardiovascular diseases remain a major global health challenge. According to the World Health Organization, cardiovascular diseases caused approximately 19.8 million deaths worldwide in 2022, representing around 32% of all global deaths.
With the latest Series B funding, Remedy Robotics aims to move its N1 platform closer to clinical trials, regulatory approval and wider hospital deployment.
Note: N1 remains under development and is not currently available for sale or clinical use in any jurisdiction. Its future adoption will depend on clinical trial results and regulatory approvals.